Events
GRASP brings patients and researchers together for small-group conversations that make cancer science more accessible, collaborative, and deeply informed by patient experience.
- This event has passed.
OPERA-01: Palazestrant vs. Standard-of-Care for ER+/HER2- MBC
August 22, 2024 @ 10:00 am - 11:00 am
Elisabeth de Kermadec will discuss the OPERA-01 phase 3 study, focusing on the efficacy of palazestrant (OP-1250) compared to standard treatments in ER+, HER2- metastatic breast cancer post endocrine therapy and CDK4/6 inhibitor resistance. We will discuss her study and review the poster “the OPERA-01 phase 3 study with us, focusing on the efficacy of palazestrant (OP-1250) compared to standard treatments in ER+, HER2- metastatic breast cancer post endocrine therapy and CDK4/6 inhibitor resistance.” which was presented at the 2024 American Society of Clinical Oncology Annual Meeting (ASCO).
